Clinical Characteristics of Methanol-Induced Optic Neuropathy: Correlation between Aetiology and Clinical Findings

Table 4

Visual acuity and treatments of eight patients.

Patient no./age range^∗/sex	Worst BCVA in acute phase		BCVA outcome		Transient BCVA improvement after treatment			Treatment^†
	BCVA	Time (after onset)	BCVA (OD/OS)	Follow-up (months)	BCVA	Time (day after onset)	Treatment
1/60S/M	NLP	3 h	NLP/NLP	42.6	FC/0.1	15	Corticosteroid	Corticosteroid
2/40S/M	NLP	1 d	NLP/NLP	39.8	FC/HM	51	Corticosteroid	Corticosteroid/HBOT
3/50S/M	NLP	2 d	NLP/NLP	38.9	FC/HM	49	Nutrition	Dialysis/corticosteroid
4/30S/M	LP	10 d	LP/LP	13.0	FC/FC	30	Corticosteroid	Corticosteroid/HBOT/PE
5/50S/M	NLP	12 h	LP/NLP	8.6	LP/FC	40	PE	Corticosteroid/HBOT/PE
6/40S/F	NLP	2 d	NLP/NLP	19.8	FC/FC	21	EPO	Corticosteroid/HBOT/EPO
7/40S/F	NLP	2 d	NLP/NLP	28.3	HM/HM	25	Corticosteroid	Dialysis/corticosteroid
8/40S/F	NLP	12 h	NLP/NLP	10.2	No improvement			Corticosteroid/HBOT/PE

M = male, F = female, BCVA = best corrected visual acuity, OD = right eye, OS = left eye, NLP = no light perception, LP = light perception, FC = finger count, HM = hand motion, HBOT = hyperbaric oxygen therapy, PE = plasmapheresis, also named plasma exchange, and EPO = erythropoietin. ^∗The age ranges were used instead of the exact ages according to the anonymization standards. ^†All treatments received before or during hospitalization are stated in time sequence. All patients received nutritional therapies, which were not listed here.